Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles Sells 43,459 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 43,459 shares of Alphatec stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $11.95, for a total transaction of $519,335.05. Following the transaction, the chief executive officer now directly owns 6,065,772 shares in the company, valued at approximately $72,485,975.40. This trade represents a 0.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Patrick Miles also recently made the following trade(s):

• On Wednesday, January 29th, Patrick Miles sold 50,000 shares of Alphatec stock. The shares were sold at an average price of $12.03, for a total transaction of $601,500.00.
• On Tuesday, January 21st, Patrick Miles sold 6,687 shares of Alphatec stock. The shares were sold at an average price of $12.00, for a total value of $80,244.00.

Alphatec Stock Down 0.5 %

Shares of Alphatec stock traded down $0.06 on Friday, hitting $11.36. 998,281 shares of the company’s stock traded hands, compared to its average volume of 1,776,835. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The firm’s 50-day moving average is $10.26 and its 200 day moving average is $8.13. The stock has a market cap of $1.61 billion, a P/E ratio of -8.88 and a beta of 1.43. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $17.34.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. R Squared Ltd bought a new stake in shares of Alphatec in the 4th quarter valued at approximately $29,000. Nisa Investment Advisors LLC boosted its holdings in Alphatec by 973.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after purchasing an additional 4,234 shares during the period. Newton One Investments LLC bought a new stake in Alphatec during the fourth quarter valued at $50,000. AlphaQuest LLC acquired a new stake in shares of Alphatec during the fourth quarter worth $80,000. Finally, Oppenheimer Asset Management Inc. bought a new position in shares of Alphatec in the 4th quarter worth about $106,000. 66.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ATEC shares. Barclays upped their target price on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. Needham & Company LLC upped their price target on Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Alphatec has a consensus rating of “Moderate Buy” and a consensus price target of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.